Rabbit Monoclonal Antibodies for Integrin Detection in FFPE Tissue

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current monoclonal antibodies fail to reliably detect integrin complexes in formalin fixed paraffin embedded (FFPE) tissue due to epitope occlusion and conformational changes caused by fixation and embedding processes, leading to ambiguous staining patterns and limited therapeutic opportunities for integrin-targeting therapies.

Innovation Solution

Development of monoclonal rabbit antibodies with specific light and heavy chain variable regions and complementarity determining regions (CDRs) that bind to the extracellular domain of integrins, capable of recognizing intact heterodimers in FFPE material, using insect-derived recombinant extracellular integrin domains as immunogens to enhance epitope accessibility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If formalin fixation and paraffin embedding are used to preserve tissue morphology, then tissue structural preservation is improved, but integrin epitope accessibility deteriorates

Engineering Contradiction:
Improvetissue structural preservationVSAvoidintegrin detection reliability
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent applies parameter changes by optimizing antibody characteristics (host species, epitope specificity, affinity) to detect integrins in FFPE tissue. Rabbit monoclonal antibodies with specific CDR sequences are designed to recognize conformational epitopes that remain accessible after formalin fixation, changing the detection parameters rather than the tissue preparation parameters.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent uses recombinant extracellular integrin domains expressed in insect cells as immunogens to generate antibodies. These recombinant copies preserve the conformational structure of native integrins, allowing the generated antibodies to recognize the same epitopes in FFPE tissue, thus copying the essential structural features needed for reliable detection.

Inventive Principle:
Principle #26Copying

2Ease of operation

If conventional monoclonal antibodies are used for integrin detection, then detection simplicity is improved, but detection accuracy in FFPE tissue deteriorates

Engineering Contradiction:
Improvedetection simplicityVSAvoidintegrin detection accuracy
Core Design Contradiction:
Ease of operationVSMeasurement precision

Solution Approach 1:

The patent applies local quality by designing antibodies with specific local characteristics (rabbit host species, particular CDR sequences, conformational epitope specificity) that enable them to function effectively in FFPE tissue. The antibody DI-17E6 has unique local properties in its variable regions that allow it to recognize integrin epitopes preserved in formalin-fixed tissue, while maintaining ease of use in standard immunohistochemistry protocols.

Inventive Principle:
Principle #3Local quality

3Reliability

If frozen tissue is used for integrin staining, then integrin epitope accessibility is improved, but tissue preservation quality deteriorates

Engineering Contradiction:
Improveintegrin staining reliabilityVSAvoidtissue preservation quality
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent inverts the conventional approach by not trying to preserve integrin epitopes through special tissue preparation (as with frozen sections), but instead generating antibodies specifically capable of detecting integrins in fixed tissue. Rather than adapting the tissue to the antibody, the antibody is adapted to detect tissue in its routinely fixed state.

Inventive Principle:
Principle #13The other way round (Inversion)

4Stability of the object's composition

If FFPE processing is used for routine histology, then morphological preservation is improved, but integrin complex detection capability deteriorates

Engineering Contradiction:
Improvemorphological preservationVSAvoidintegrin complex detection
Core Design Contradiction:
Stability of the object's compositionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent applies preliminary action by pre-generating rabbit monoclonal antibodies with specific conformational epitope recognition capability before tissue processing. These antibodies are specifically designed to recognize integrin epitopes that remain accessible after FFPE processing, so no additional preliminary tissue treatment (like antigen retrieval) is needed beyond standard FFPE protocol.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP2467401B1Antibodies for the detection of integrin complexes in FFPE material
Publication Date: 2017.01.18 MERCK PATENT GMBH
  • EP2467401B1 patent drawingFigure 1A~1J
  • EP2467401B1 patent drawingFigure 2
  • EP2467401B1 patent drawingFigure 3

AI summary

The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.